Building a tuberculosis-free world: The Lancet Commission on tuberculosis

[1]  N. Arinaminpathy,et al.  Assessing tuberculosis control priorities in high-burden settings: a modelling approach. , 2019, The Lancet. Global health.

[2]  N. Arinaminpathy,et al.  Supplement to: Constructing care cascades for active tuberculosis: a strategy for program monitoring and identifying gaps in quality of care Corresponding author: , 2019 .

[3]  J. Hammitt,et al.  Valuing Mortality Risk Reductions in Global Benefit-Cost Analysis , 2019, Journal of Benefit-Cost Analysis.

[4]  M. Pai,et al.  Tuberculosis: treatment failure, or failure to treat? Lessons from India and South Africa , 2019, BMJ Global Health.

[5]  Jingtao Gao,et al.  WHO treatment guidelines for isoniazid-resistant tuberculosis: supplement to the WHO treatment guidelines for drug-resistant tuberculosis , 2018 .

[6]  P. Shete,et al.  Message to world leaders: we cannot end tuberculosis without addressing the social and economic burden of the disease. , 2018, The Lancet. Global health.

[7]  A. Kekitiinwa,et al.  Decentralisation of child tuberculosis services increases case finding and uptake of preventive therapy in Uganda. , 2018, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[8]  S. Harikrishnan,et al.  Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017. , 2018, Lancet.

[9]  A. Fauci.  Addressing the Tuberculosis Epidemic: 21st Century Research for an Ancient Disease , 2018, JAMA.

[10]  D. Jamison,et al.  Alma-Ata at 40 years: reflections from the Lancet Commission on Investing in Health , 2018, The Lancet.

[11]  H. Jenkins,et al.  Potential effect of household contact management on childhood tuberculosis: a mathematical modelling study , 2018, The Lancet. Global health.

[12]  M. Demoitié,et al.  Phase 2b placebo-controlled trial of M72/AS01E candidate vaccine to prevent active tuberculosis in adults , 2018, The New England journal of medicine.

[13]  B. Bloom.  New Promise for Vaccines against Tuberculosis. , 2018, The New England journal of medicine.

[14]  S. Sudhir,et al.  Anti-tuberculosis treatment stewardship in a private tertiary care hospital in South India. , 2018, Public health action.

[15]  Tanya Marchant,et al.  High-quality health systems in the Sustainable Development Goals era: time for a revolution , 2018, The Lancet. Global health.

[16]  M. Pai,et al.  Variations in the quality of tuberculosis care in urban India: A cross-sectional, standardized patient study in two cities , 2018, PLoS medicine.

[17]  Gavin Yamey,et al.  Funding global health product R&D: the Portfolio-To-Impact Model (P2I), a new tool for modelling the impact of different research portfolios , 2018, Gates open research.

[18]  S. Self,et al.  Prevention of Infection with Mycobacterium tuberculosis by H4:IC31® Vaccination or BCG Revaccination in Adolescents , 2018, The New England journal of medicine.

[19]  P. Jha,et al.  Benefits and Costs of the Health Targets for the Post-2015 Development Agenda , 2018, Prioritizing Development.

[20]  Y. Jain,et al.  Household-Contact Investigation for Detection of Tuberculosis in Vietnam. , 2018, The New England journal of medicine.

[21]  Lindsay C. Dahora,et al.  Developing new health technologies for neglected diseases: a pipeline portfolio review and cost model , 2018, Gates open research.

[22]  R. Horton.  Offline: UHC—one promise and two misunderstandings , 2018, The Lancet.

[23]  V. Cox,et al.  Global programmatic use of bedaquiline and delamanid for the treatment of multidrug-resistant tuberculosis. , 2018, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[24]  T. Cohen,et al.  Pan-tuberculosis regimens: an argument for. , 2018, The Lancet. Respiratory medicine.

[25]  M. Sculpher,et al.  Supporting the development of a health benefits package in Malawi , 2018, BMJ Global Health.

[26]  K. Dheda,et al.  Pan-tuberculosis regimens: an argument against. , 2018, The Lancet. Respiratory medicine.

[27]  C. Evans,et al.  Addressing social determinants to end tuberculosis , 2018, The Lancet.

[28]  Daniel J. Carter,et al.  The impact of social protection and poverty elimination on global tuberculosis incidence: a statistical modelling analysis of Sustainable Development Goal 1 , 2018, The Lancet. Global health.

[29]  C. Dye.  Expanded health systems for sustainable development , 2018, Science.

[30]  M. Yotebieng,et al.  Funding innovation in neglected diseases , 2018, British Medical Journal.

[31]  A. Pablos-Mendez,et al.  A New World Health Era , 2018, Global Health: Science and Practice.

[32]  M. Nicol,et al.  Precision medicine for drug-resistant tuberculosis in high-burden countries: is individualised treatment desirable and feasible? , 2018, The Lancet. Infectious diseases.

[33]  Syed Mustafa Ali,et al.  Loss-to-follow-up and delay to treatment initiation in Pakistan’s national tuberculosis control programme , 2018, BMC Public Health.

[34]  M. Mckee,et al.  People- and patient-centred care for tuberculosis: models of care for tuberculosis. , 2018, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[35]  J. Richardus,et al.  Catastrophic total costs in tuberculosis-affected households and their determinants since Indonesia’s implementation of universal health coverage , 2018, Infectious Diseases of Poverty.

[36]  A. Fauci,et al.  Reimagining the Research Approach to Tuberculosis† , 2018, The American journal of tropical medicine and hygiene.

[37]  Duc Cuong Pham,et al.  Video Directly Observed Therapy to support adherence with treatment for tuberculosis in Vietnam: A prospective cohort study. , 2017, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[38]  A. Gawande,et al.  Universal health coverage and intersectoral action for health: key messages from Disease Control Priorities, 3rd edition , 2017, The Lancet.

[39]  M. Luengo-Oroz,et al.  Using big data for non-communicable disease surveillance. , 2017, The lancet. Diabetes & endocrinology.

[40]  Khai Hoan Tram,et al.  Gaps in the child tuberculosis care cascade in 32 rural communities in Uganda and Kenya , 2017, Journal of clinical tuberculosis and other mycobacterial diseases.

[41]  Shicheng Yu,et al.  The burden and challenges of tuberculosis in China: findings from the Global Burden of Disease Study 2015 , 2017, Scientific Reports.

[42]  G. Hart,et al.  TB and HIV stigma compounded by threatened masculinity: implications for TB health-care seeking in Malawi. , 2017, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[43]  N. Engel,et al.  Defining the research agenda to measure and reduce tuberculosis stigmas. , 2017, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[44]  S. Koenig,et al.  The devil we know: is the use of injectable agents for the treatment of MDR-TB justified? , 2017, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[45]  N. Ford,et al.  Time to treatment for rifampicin-resistant tuberculosis: systematic review and meta-analysis , 2017, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[46]  E. Wouters,et al.  Evidence-based interventions to reduce tuberculosis stigma: a systematic review. , 2017, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[47]  R. Salamon,et al.  Effect of isoniazid preventive therapy on risk of death in west African, HIV-infected adults with high CD4 cell counts: long-term follow-up of the Temprano ANRS 12136 trial. , 2017, The Lancet. Global health.

[48]  R. Chaisson,et al.  Preventing tuberculosis in people with HIV-no more excuses. , 2017, The Lancet. Global health.

[49]  B. Pescosolido,et al.  Communication Strategies to Counter Stigma and Improve Mental Illness and Substance Use Disorder Policy. , 2017, Psychiatric services.

[50]  S. Rozelle,et al.  Tuberculosis detection and the challenges of integrated care in rural China: A cross-sectional standardized patient study , 2017, PLoS medicine.

[51]  R. Shretta,et al.  Regional initiatives for malaria elimination: Building and maintaining partnerships , 2017, PLoS medicine.

[52]  G. Theron,et al.  The South African Tuberculosis Care Cascade: Estimated Losses and Methodological Challenges , 2017, The Journal of infectious diseases.

[53]  K. Floyd,et al.  Harnessing the Power of Data to Guide Local Action and End Tuberculosis , 2017, The Journal of infectious diseases.

[54]  Jessie Brown,et al.  Using Patient-Pathway Analysis to Inform a Differentiated Program Response to Tuberculosis: The Case of Kenya , 2017, The Journal of infectious diseases.

[55]  D. Chin,et al.  Conducting Patient-Pathway Analysis to Inform Programming of Tuberculosis Services: Methods , 2017, The Journal of infectious diseases.

[56]  D. Chin,et al.  Finding the Missing Tuberculosis Patients , 2017, The Journal of infectious diseases.

[57]  D. Chin,et al.  Finding the Missing Patients With Tuberculosis: Lessons Learned From Patient-Pathway Analyses in 5 Countries , 2017, The Journal of infectious diseases.

[58]  Mike Osberg,et al.  Quality Tuberculosis Care in Indonesia: Using Patient Pathway Analysis to Optimize Public–Private Collaboration , 2017, The Journal of infectious diseases.

[59]  N. McGrath,et al.  Impact of Point‐of‐Care Xpert MTB/RIF on Tuberculosis Treatment Initiation. A Cluster‐randomized Trial , 2017, American journal of respiratory and critical care medicine.

[60]  V. Gudnason,et al.  Comparison of Summer and Winter Objectively Measured Physical Activity and Sedentary Behavior in Older Adults: Age, Gene/Environment Susceptibility Reykjavik Study , 2017, International journal of environmental research and public health.

[61]  S. Dorman,et al.  Evaluation of a Rapid Molecular Drug‐Susceptibility Test for Tuberculosis , 2017, The New England journal of medicine.

[62]  T. A. Ghebreyesus.  All roads lead to universal health coverage. , 2017, The Lancet. Global health.

[63]  D. Havlir,et al.  Predictors of Retention in HIV Care Among Youth (15–24) in a Universal Test-and-Treat Setting in Rural Kenya , 2017, Journal of acquired immune deficiency syndromes.

[64]  Y. Manabe,et al.  Text messaging to decrease tuberculosis treatment attrition in TB-HIV coinfection in Uganda , 2017, Patient preference and adherence.

[65]  D. Alland,et al.  The New Xpert MTB/RIF Ultra: Improving Detection of Mycobacterium tuberculosis and Resistance to Rifampin in an Assay Suitable for Point-of-Care Testing , 2017, mBio.

[66]  Helen E Jenkins,et al.  The global burden of tuberculosis mortality in children: a mathematical modelling study , 2017, The Lancet. Global health.

[67]  David G. Sterling,et al.  Discovery and Validation of a Six-Marker Serum Protein Signature for the Diagnosis of Active Pulmonary Tuberculosis , 2017, Journal of Clinical Microbiology.

[68]  M. Pai,et al.  Implementation of Xpert MTB/RIF in 22 high tuberculosis burden countries: are we making progress? , 2017, European Respiratory Journal.

[69]  K. Maitland,et al.  Enhanced Prophylaxis plus Antiretroviral Therapy for Advanced HIV Infection in Africa , 2017, The New England journal of medicine.

[70]  John Stover,et al.  Financing transformative health systems towards achievement of the health Sustainable Development Goals: a model for projected resource needs in 67 low-income and middle-income countries , 2017, The Lancet. Global health.

[71]  Kelley Lee,et al.  The Role of Civil Society Organizations in Monitoring the Global AIDS Response , 2017, AIDS and Behavior.

[72]  R. Coker,et al.  Risk factors that may be driving the emergence of drug resistance in tuberculosis patients treated in Yangon, Myanmar , 2017, PloS one.

[73]  Ana Goicoechea,et al.  Use of standardised patients to assess quality of healthcare in Nairobi, Kenya: a pilot, cross-sectional study with international comparisons , 2017, BMJ Global Health.

[74]  M. Pai,et al.  Tuberculosis innovations mean little if they cannot save lives , 2017, eLife.

[75]  Marta R Prescott,et al.  Quality improvement intervention to increase adherence to ART prescription policy at HIV treatment clinics in Lusaka, Zambia: A cluster randomized trial , 2017, PloS one.

[76]  Qian Gao,et al.  Transmission of multidrug-resistant Mycobacterium tuberculosis in Shanghai, China: a retrospective observational study using whole-genome sequencing and epidemiological investigation. , 2017, The Lancet. Infectious diseases.

[77]  H. Alsdurf,et al.  Quality of tuberculosis care in high burden countries: the urgent need to address gaps in the care cascade. , 2017, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[78]  N. Engel,et al.  Tuberculosis stigma as a social determinant of health: a systematic mapping review of research in low incidence countries. , 2017, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[79]  Yemane Weldu,et al.  Patients' Delay in Seeking Health Care for Tuberculosis Diagnosis in East Gojjam Zone, Northwest Ethiopia. , 2017, The American journal of tropical medicine and hygiene.

[80]  F. Cobelens,et al.  Delays and loss to follow-up before treatment of drug-resistant tuberculosis following implementation of Xpert MTB/RIF in South Africa: A retrospective cohort study , 2017, PLoS medicine.

[81]  Y. Cherrah,et al.  National strategy for the integration of pharmacovigilance in the Moroccan TB Control Program , 2017, The Pan African medical journal.

[82]  A. Narechania,et al.  Transmission of Extensively Drug‐Resistant Tuberculosis in South Africa , 2017, The New England journal of medicine.

[83]  E. McBryde,et al.  High rates of multidrug-resistant and rifampicin-resistant tuberculosis among re-treatment cases: where do they come from? , 2017, BMC Infectious Diseases.

[84]  S. Graham.  The management of infection with Mycobacterium tuberculosis in young children post-2015: an opportunity to close the policy-practice gap , 2017, Expert review of respiratory medicine.

[85]  M. Pai,et al.  Location, location, location: tuberculosis services in highest burden countries. , 2016, The Lancet. Global health.

[86]  Wei Tsang Ooi,et al.  Prospective single-arm interventional pilot study to assess a smartphone-based system for measuring and supporting adherence to medication , 2016, BMJ Open.

[87]  H. Jenkins.  Global burden of childhood tuberculosis , 2016, Pneumonia.

[88]  T. Ottenhoff,et al.  Correlates of tuberculosis risk: predictive biomarkers for progression to active tuberculosis , 2016, European Respiratory Journal.

[89]  Richard G. White,et al.  Cost-effectiveness and resource implications of aggressive action on tuberculosis in China, India, and South Africa: a combined analysis of nine models. , 2016, The Lancet. Global health.

[90]  Rachel Glennerster,et al.  Impact of a Daily SMS Medication Reminder System on Tuberculosis Treatment Outcomes: A Randomized Controlled Trial , 2016, PloS one.

[91]  M. Pai,et al.  Use of standardised patients to assess antibiotic dispensing for tuberculosis by pharmacies in urban India: a cross-sectional study , 2016, The Lancet. Infectious diseases.

[92]  N. Arinaminpathy,et al.  The number of privately treated tuberculosis cases in India: an estimation from drug sales data , 2016, The Lancet. Infectious diseases.

[93]  H. Alsdurf,et al.  The cascade of care in diagnosis and treatment of latent tuberculosis infection: a systematic review and meta-analysis. , 2016, The Lancet. Infectious diseases.

[94]  M. Pai,et al.  Tuberculosis Diagnostics: State of the Art and Future Directions. , 2016, Microbiology spectrum.

[95]  Richard G. White,et al.  Feasibility of achieving the 2025 WHO global tuberculosis targets in South Africa, China, and India: a combined analysis of 11 mathematical models , 2016, The Lancet. Global health.

[96]  S. Swaminathan,et al.  The Tuberculosis Cascade of Care in India’s Public Sector: A Systematic Review and Meta-analysis , 2016, PLoS medicine.

[97]  Peter J Dodd,et al.  The Global Burden of Latent Tuberculosis Infection: A Re-estimation Using Mathematical Modelling , 2016, PLoS medicine.

[98]  C. Sismanidis,et al.  Global burden of drug-resistant tuberculosis in children: a mathematical modelling study. , 2016, The Lancet. Infectious diseases.

[99]  Martha A. Tesfalul,et al.  Evaluation of a Mobile Health Approach to Tuberculosis Contact Tracing in Botswana , 2016, Journal of health communication.

[100]  Richard G. White,et al.  Sex Differences in Tuberculosis Burden and Notifications in Low- and Middle-Income Countries: A Systematic Review and Meta-analysis , 2016, PLoS medicine.

[101]  M. Pai,et al.  Computer-aided detection of pulmonary tuberculosis on digital chest radiographs: a systematic review. , 2016, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[102]  Shun-Fa Yang,et al.  Impacts of 12-dose regimen for latent tuberculosis infection , 2016, Medicine.

[103]  Julia Smith,et al.  Civil society: the catalyst for ensuring health in the age of sustainable development , 2016, Globalization and Health.

[104]  D. Jamison,et al.  Why has under-5 mortality decreased at such different rates in different countries? , 2016, Journal of health economics.

[105]  B. Agins,et al.  A National Organizational Assessment (NOA) to Build Sustainable Quality Management Programs in Low- and Middle- Income Countries. , 2016, Joint Commission journal on quality and patient safety.

[106]  Á. Taype-Rondan,et al.  Grupos de apoyo para pacientes con tuberculosis en Facebook , 2016 .

[107]  H. Jenkins,et al.  Two methods for setting child-focused tuberculosis care targets. , 2016, Public health action.

[108]  L. London,et al.  Multidrug-Resistant TB , 2016, Health and human rights.

[109]  Evan Lyon,et al.  Developing a Human Rights-Based Approach to Tuberculosis , 2016, Health and human rights.

[110]  I. Henry,et al.  Falling Short of the Rights to Health and Scientific Progress , 2016, Health and human rights.

[111]  B. van Ginneken,et al.  An automated tuberculosis screening strategy combining X-ray-based computer-aided detection and clinical information , 2016, Scientific Reports.

[112]  Daniel E. Zak,et al.  A prospective blood RNA signature for tuberculosis disease risk , 2016, The Lancet.

[113]  K. Sagili,et al.  “When Treatment Is More Challenging than the Disease”: A Qualitative Study of MDR-TB Patient Retention , 2016, PloS one.

[114]  D. Rasella,et al.  Effectiveness of a conditional cash transfer programme on TB cure rate: a retrospective cohort study in Brazil. , 2016, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[115]  J. Furin,et al.  Global Progress and Challenges in Implementing New Medications for Treating Multidrug-Resistant Tuberculosis , 2016, Emerging infectious diseases.

[116]  Purvesh Khatri,et al.  Genome-wide expression for diagnosis of pulmonary tuberculosis: a multicohort analysis. , 2016, The Lancet. Respiratory medicine.

[117]  M. Kruk,et al.  Transforming Global Health by Improving the Science of Scale-Up , 2016, PLoS biology.

[118]  R. Garfein,et al.  Monitoring Therapy Adherence of Tuberculosis Patients by using Video-Enabled Electronic Devices , 2016, Emerging infectious diseases.

[119]  S. Graham,et al.  Childhood TB: can the End TB Strategy deliver? , 2016, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[120]  S. Swaminathan,et al.  Translational Research for Tuberculosis Elimination: Priorities, Challenges, and Actions , 2016, PLoS medicine.

[121]  S. Zhan,et al.  Adverse Events Associated With the Treatment of Multidrug-Resistant Tuberculosis: A Systematic Review and Meta-analysis , 2016, American journal of therapeutics.

[122]  R. Atun,et al.  Innovative financing for HIV response in sub–Saharan Africa , 2016, Journal of global health.

[123]  N. Ikegami,et al.  Moving towards universal health coverage: lessons from 11 country studies , 2016, The Lancet.

[124]  P. V. van Helden,et al.  The diagnostic accuracy of the MTBDRplus and MTBDRsl assays for drug-resistant TB detection when performed on sputum and culture isolates , 2016, Scientific Reports.

[125]  J. Zelner,et al.  Identifying Hotspots of Multidrug-Resistant Tuberculosis Transmission Using Spatial and Molecular Genetic Data. , 2016, The Journal of infectious diseases.

[126]  S. Kassaye,et al.  Improving HIV Surveillance Data for Public Health Action in Washington, DC: A Novel Multiorganizational Data-Sharing Method , 2016, JMIR public health and surveillance.

[127]  M. Claeson,et al.  Global Financing Facility: where will the funds come from? , 2016, The Lancet.

[128]  Thomas R Rogers,et al.  Rapid, comprehensive, and affordable mycobacterial diagnosis with whole-genome sequencing: a prospective study , 2016, The Lancet. Respiratory medicine.

[129]  F. Cobelens,et al.  Data for action: collection and use of local data to end tuberculosis , 2015, The Lancet.

[130]  T. Bärnighausen,et al.  Stopping tuberculosis: a biosocial model for sustainable development , 2015, The Lancet.

[131]  R. Chaisson,et al.  Controlling the seedbeds of tuberculosis: diagnosis and treatment of tuberculosis infection , 2015, The Lancet.

[132]  S. Swaminathan,et al.  Stopping the body count: a comprehensive approach to move towards zero tuberculosis deaths , 2015, The Lancet.

[133]  N. Arinaminpathy,et al.  Understanding the incremental value of novel diagnostic tests for tuberculosis , 2015, Nature.

[134]  N. Solovieva,et al.  Trends in molecular epidemiology of drug-resistant tuberculosis in Republic of Karelia, Russian Federation , 2015, BMC Microbiology.

[135]  G. Bloemberg,et al.  Acquired Resistance to Bedaquiline and Delamanid in Therapy for Tuberculosis. , 2015, The New England journal of medicine.

[136]  E. Nardell,et al.  Turning off the tap: stopping tuberculosis transmission through active case-finding and prompt effective treatment , 2015, The Lancet.

[137]  M. Pai,et al.  Use of standardised patients to assess quality of tuberculosis care: a pilot, cross-sectional study. , 2015, The Lancet. Infectious diseases.

[138]  Hsien-Ho Lin,et al.  Ambient air pollution and risk of tuberculosis: a cohort study , 2015, Occupational and Environmental Medicine.

[139]  C. Karp,et al.  Transformative tools for tackling tuberculosis , 2015, The Journal of experimental medicine.

[140]  Phelim Bradley,et al.  Whole-genome sequencing for prediction of Mycobacterium tuberculosis drug susceptibility and resistance: a retrospective cohort study , 2015, The Lancet. Infectious diseases.

[141]  M. Uplekar,et al.  WHO's End TB Strategy: From stopping to ending the global TB epidemic. , 2015, The Indian journal of tuberculosis.

[142]  R. Belknap,et al.  Latent Mycobacterium tuberculosis Infection. , 2015, The New England journal of medicine.

[143]  K. Floyd,et al.  National tuberculosis prevalence surveys in Asia, 1990–2012: an overview of results and lessons learned , 2015, Tropical medicine & international health : TM & IH.

[144]  C. Sismanidis,et al.  The first national tuberculosis prevalence survey of Lao PDR (2010–2011) , 2015, Tropical medicine & international health : TM & IH.

[145]  C. Evans,et al.  Designing and implementing a socioeconomic intervention to enhance TB control: operational evidence from the CRESIPT project in Peru , 2015, BMC Public Health.

[146]  B. van Ginneken,et al.  Automated chest-radiography as a triage for Xpert testing in resource-constrained settings: a prospective study of diagnostic accuracy and costs , 2015, Scientific Reports.

[147]  S. Resch,et al.  Defeating AIDS—advancing global health , 2015, The Lancet.

[148]  L. Scott,et al.  The patient impact of point-of-care vs. laboratory placement of Xpert(®) MTB/RIF. , 2015, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[149]  Bruce Agins,et al.  A quality improvement approach to capacity building in low- and middle-income countries , 2015, AIDS.

[150]  G. Gore,et al.  Quality of tuberculosis care in India: a systematic review. , 2015, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[151]  Anna Hung,et al.  A review of how the quality of HIV clinical services has been evaluated or improved , 2015, International journal of STD & AIDS.

[152]  M. Uplekar,et al.  Achieving Systemic and Scalable Private Sector Engagement in Tuberculosis Care and Prevention in Asia , 2015, PLoS medicine.

[153]  R. Chaisson,et al.  Latent Mycobacterium tuberculosis infection. , 2015, The New England journal of medicine.

[154]  E. Goemaere,et al.  The need to accelerate access to new drugs for multidrug-resistant tuberculosis , 2015, Bulletin of the World Health Organization.

[155]  Snider D.E.Jr..  The relationship between tuberculosis and silicosis. , 2015 .

[156]  D. Mitchison,et al.  Influence of initial drug resistance on the response to short-course chemotherapy of pulmonary tuberculosis. , 2015, The American review of respiratory disease.

[157]  D. Snider,et al.  Isoniazid prophylaxis among Alaskan Eskimos: a final report of the bethel isoniazid studies. , 2015, The American review of respiratory disease.

[158]  W. Morgan.  The relationship between tuberculosis and silicosis. , 2015, The American review of respiratory disease.

[159]  A. Vassall,et al.  Costs to Health Services and the Patient of Treating Tuberculosis: A Systematic Literature Review , 2015, PharmacoEconomics.

[160]  Christopher Gilpin,et al.  WHO's new End TB Strategy , 2015, The Lancet.

[161]  Shenglan Tang,et al.  Public-private mix for tuberculosis care and control: a systematic review. , 2015, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[162]  S. Swaminathan,et al.  Prevalence and Risk Factors for Adult Pulmonary Tuberculosis in a Metropolitan City of South India , 2015, PloS one.

[163]  Marco Schito,et al.  Tuberculosis diagnostics in 2015: landscape, priorities, needs, and prospects. , 2015, The Journal of infectious diseases.

[164]  G. Hart,et al.  ‘For a mere cough, men must just chew Conjex, gain strength, and continue working’: the provider construction and tuberculosis care-seeking implications in Blantyre, Malawi , 2015, Global health action.

[165]  N. Arinaminpathy,et al.  The Global Drug Facility as an intervention in the market for tuberculosis drugs , 2015, Bulletin of the World Health Organization.

[166]  I. Mokrousov.  Molecular structure of Mycobacterium tuberculosis population in Russia and its interaction with neighboring countries. , 2015, International journal of mycobacteriology.

[167]  D. Jamison,et al.  Universal public finance of tuberculosis treatment in India: an extended cost-effectiveness analysis. , 2015, Health economics.

[168]  Thierry Cordier-Lassalle,et al.  Reducing the price of treatment for multidrug-resistant tuberculosis through the Global Drug Facility , 2015, Bulletin of the World Health Organization.

[169]  D. Menzies,et al.  Modeling the impact of tuberculosis interventions on epidemiologic outcomes and health system costs , 2015, BMC Public Health.

[170]  A. Vassall,et al.  Impact of reduced hospitalisation on the cost of treatment for drug-resistant tuberculosis in South Africa. , 2015, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[171]  Leo Anthony Celi,et al.  Big data in global health: improving health in low- and middle-income countries , 2015, Bulletin of the World Health Organization.

[172]  V. Fofanov,et al.  Genomic epidemiology of multidrug-resistant Mycobacterium tuberculosis during transcontinental spread. , 2015, The Journal of infectious diseases.

[173]  M. L. van der Walt,et al.  Treatment outcomes of patients with multidrug-resistant and extensively drug-resistant tuberculosis according to drug susceptibility testing to first- and second-line drugs: an individual patient data meta-analysis. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[174]  A. Azman,et al.  How much is tuberculosis screening worth? Estimating the value of active case finding for tuberculosis in South Africa, China, and India , 2014, BMC Medicine.

[175]  P. Butcher,et al.  High-dose rifapentine with moxifloxacin for pulmonary tuberculosis. , 2014, The New England journal of medicine.

[176]  A. Crook,et al.  Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis. , 2014, The New England journal of medicine.

[177]  A. Azman,et al.  Transforming the fight against tuberculosis: targeting catalysts of transmission. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[178]  Carmen Z. Suarez,et al.  Extensive drug resistance acquired during treatment of multidrug-resistant tuberculosis. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[179]  Richard G. White,et al.  Impact and cost-effectiveness of new tuberculosis vaccines in low- and middle-income countries , 2014, Proceedings of the National Academy of Sciences.

[180]  T. Hwang,et al.  Global Financing and Long-Term Technical Assistance for Multidrug-Resistant Tuberculosis: Scaling Up Access to Treatment , 2014, PLoS medicine.

[181]  K. Floyd,et al.  Beyond UHC: Monitoring Health and Social Protection Coverage in the Context of Tuberculosis Care and Prevention , 2014, PLoS medicine.

[182]  W. Brakel,et al.  How to reduce stigma in leprosy--a systematic literature review. , 2014, Leprosy review.

[183]  Richard G. White,et al.  Drivers and Trajectories of Resistance to New First-Line Drug Regimens for Tuberculosis , 2014, Open forum infectious diseases.

[184]  G. Maartens,et al.  Isoniazid plus antiretroviral therapy to prevent tuberculosis: a randomised double-blind, placebo-controlled trial , 2014, The Lancet.

[185]  R. Chaisson,et al.  Impact of Isoniazid Preventive Therapy for HIV-Infected Adults in Rio de Janeiro, Brazil: An Epidemiological Model , 2014, Journal of acquired immune deficiency syndromes.

[186]  Ross J. Harris,et al.  Effect of BCG vaccination against Mycobacterium tuberculosis infection in children: systematic review and meta-analysis , 2014, BMJ : British Medical Journal.

[187]  P. Dodd,et al.  Burden of childhood tuberculosis in 22 high-burden countries: a mathematical modelling study. , 2014, The Lancet. Global health.

[188]  C. Evans,et al.  Defining Catastrophic Costs and Comparing Their Importance for Adverse Tuberculosis Outcome with Multi-Drug Resistance: A Prospective Cohort Study, Peru , 2014, PLoS medicine.

[189]  A. Lombardi,et al.  Mycobacterium tuberculosis Beijing family: analysis of the epidemiological and clinical factors associated with an emerging lineage in the urban area of Milan. , 2014, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.

[190]  Fei Huang,et al.  Tuberculosis prevalence in China, 1990–2010; a longitudinal analysis of national survey data , 2014, The Lancet.

[191]  Richard G. White,et al.  Population-Level Impact of Shorter-Course Regimens for Tuberculosis: A Model-Based Analysis , 2014, PloS one.

[192]  R. Black,et al.  Importance of tuberculosis control to address child survival , 2014, The Lancet.

[193]  Marcello Pagano,et al.  Incidence of multidrug-resistant tuberculosis disease in children: systematic review and global estimates , 2014, The Lancet.

[194]  R. Chaisson,et al.  Tuberculosis preventive therapy: an underutilised strategy to reduce individual risk of TB and contribute to TB control. , 2014, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.

[195]  M. Pai,et al.  Tuberculosis diagnostics: which target product profiles should be prioritised? , 2014, European Respiratory Journal.

[196]  D. von Delft,et al.  The evolving role of advocacy in tuberculosis. , 2014, The Lancet. Respiratory medicine.

[197]  C. Sreeramareddy,et al.  Delays in diagnosis and treatment of pulmonary tuberculosis in India: a systematic review. , 2014, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[198]  M. Raviglione,et al.  Financial burden for tuberculosis patients in low- and middle-income countries: a systematic review , 2014, European Respiratory Journal.

[199]  J. Glynn,et al.  Pre-treatment loss to follow-up in tuberculosis patients in low- and lower-middle-income countries and high-burden countries: a systematic review and meta-analysis. , 2014, Bulletin of the World Health Organization.

[200]  L. Richter,et al.  Economic Support to Patients in HIV and TB Grants in Rounds 7 and 10 from the Global Fund to Fight AIDS, Tuberculosis and Malaria , 2014, PloS one.

[201]  S. Chandra,et al.  Resurrecting social infrastructure as a determinant of urban tuberculosis control in Delhi, India , 2014, Health Research Policy and Systems.

[202]  M. Pai,et al.  Modeling the impact of alternative strategies for rapid molecular diagnosis of tuberculosis in Southeast Asia. , 2013, American journal of epidemiology.

[203]  Gavin Yamey,et al.  Global health 2035: a world converging within a generation , 2013, The Lancet.

[204]  T. Sterling,et al.  Cost-effectiveness of a 12-dose regimen for treating latent tuberculous infection in the United States. , 2013, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[205]  G. Marks,et al.  Household contact investigation for tuberculosis in Vietnam: study protocol for a cluster randomized controlled trial , 2013, Trials.

[206]  N. Arinaminpathy,et al.  The Global Drug Facility and its role in the market for tuberculosis drugs , 2013, The Lancet.

[207]  A. Azman,et al.  Population-Level Impact of Active Tuberculosis Case Finding in an Asian Megacity , 2013, PloS one.

[208]  Tom Paulson,et al.  Epidemiology: A mortal foe , 2013, Nature.

[209]  R. Hayes,et al.  Effect of household and community interventions on the burden of tuberculosis in southern Africa: the ZAMSTAR community-randomised trial , 2013, The Lancet.

[210]  M. Uplekar,et al.  Programmatic approaches to screening for active tuberculosis. , 2013, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[211]  B. Slingsby,et al.  The Global Health Innovative Technology (GHIT) Fund: financing medical innovations for neglected populations. , 2013, The Lancet. Global health.

[212]  W. Venter,et al.  Prevalence, risk factors and risk perception of tuberculosis infection among medical students and healthcare workers in Johannesburg, South Africa. , 2013, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.

[213]  T. Ahmed,et al.  Pulmonary Tuberculosis in Severely-malnourished or HIV-infected Children with Pneumonia: A Review , 2013, Journal of health, population, and nutrition.

[214]  Marie Lynn Miranda,et al.  Geographic health information systems: a platform to support the 'triple aim'. , 2013, Health affairs.

[215]  V. Jarlier,et al.  A surge of MDR and XDR tuberculosis in France among patients born in the Former Soviet Union. , 2013, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[216]  K. Floyd,et al.  Domestic and donor financing for tuberculosis care and control in low-income and middle-income countries: an analysis of trends, 2002-11, and requirements to meet 2015 targets. , 2013, The Lancet. Global health.

[217]  N. Ford,et al.  Decentralisation of multidrug-resistant-tuberculosis care and management. , 2013, The Lancet. Infectious diseases.

[218]  P. Brassard,et al.  Screening employees of services for homeless individuals in Montréal for tuberculosis infection. , 2013, Journal of infection and public health.

[219]  D. Berkvens,et al.  From Multidrug- to Extensively Drug-Resistant Tuberculosis: Upward Trends as Seen from a 15-Year Nationwide Study , 2013, PloS one.

[220]  R. O’Toole,et al.  Phylogenetic lineages of tuberculosis isolates in New Zealand and their association with patient demographics. , 2013, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[221]  J. Golub,et al.  The benefits to communities and individuals of screening for active tuberculosis disease: a systematic review. , 2013, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[222]  C. Dye,et al.  Prospects for tuberculosis elimination. , 2013, Annual review of public health.

[223]  A. Toczek,et al.  Strategies for reducing treatment default in drug-resistant tuberculosis: systematic review and meta-analysis [Review article]. , 2013, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[224]  K. Lönnroth,et al.  Free tuberculosis diagnosis and treatment are not enough: patient cost evidence from three continents. , 2013, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[225]  Frank Mueller‐Langer,et al.  Neglected infectious diseases: Are push and pull incentive mechanisms suitable for promoting drug development research? , 2013, Health Economics, Policy and Law.

[226]  E. Mupere,et al.  Childhood tuberculosis and malnutrition. , 2012, The Journal of infectious diseases.

[227]  D. Nash,et al.  Implementation of tuberculosis infection control measures at HIV care and treatment sites in sub-Saharan Africa. , 2012, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[228]  Rifat Atun,et al.  Research on Implementation of Interventions in Tuberculosis Control in Low- and Middle-Income Countries: A Systematic Review , 2012, PLoS medicine.

[229]  T. Yoshiyama,et al.  Epidemiological impact of mass tuberculosis screening: a 2-year follow-up after a national prevalence survey. , 2012, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[230]  E. Sullivan-marx,et al.  The paradigm shift. , 2012, The Nursing clinics of North America.

[231]  M. Murray,et al.  Tuberculosis and Poverty: Why Are the Poor at Greater Risk in India? , 2012, PloS one.

[232]  H. Jenkins,et al.  Assessing spatial heterogeneity of multidrug-resistant tuberculosis in a high-burden country , 2012, European Respiratory Journal.

[233]  David L. Smith,et al.  Quantifying the Impact of Human Mobility on Malaria , 2012, Science.

[234]  A. Harries,et al.  Screening of patients with tuberculosis for diabetes mellitus in China , 2012, Tropical medicine & international health : TM & IH.

[235]  G. Marks,et al.  Contact investigation for tuberculosis: a systematic review and meta-analysis , 2012, European Respiratory Journal.

[236]  S. Satyanarayana,et al.  How Did the TB Patients Reach DOTS Services in Delhi? A Study of Patient Treatment Seeking Behavior , 2012, PloS one.

[237]  Marcos Burgos,et al.  Multidrug Resistant Pulmonary Tuberculosis Treatment Regimens and Patient Outcomes: An Individual Patient Data Meta-analysis of 9,153 Patients , 2012, PLoS medicine.

[238]  R. Warren,et al.  Drug-Resistant Tuberculosis Transmission and Resistance Amplification within Families , 2012, Emerging infectious diseases.

[239]  S. Lawn,et al.  Feasibility, Yield, and Cost of Active Tuberculosis Case Finding Linked to a Mobile HIV Service in Cape Town, South Africa: A Cross-sectional Study , 2012, PLoS medicine.

[240]  J. Creswell,et al.  Engaging the private sector to increase tuberculosis case detection: an impact evaluation study. , 2012, The Lancet. Infectious diseases.

[241]  R. Chaisson,et al.  Antiretroviral Therapy for Prevention of Tuberculosis in Adults with HIV: A Systematic Review and Meta-Analysis , 2012, PLoS medicine.

[242]  R. Gie,et al.  Modelling the cost-effectiveness of strategies to prevent tuberculosis in child contacts in a high-burden setting , 2012, Thorax.

[243]  P. Godfrey-Faussett,et al.  Hearing loss in patients on treatment for drug-resistant tuberculosis , 2012, European Respiratory Journal.

[244]  Yu Wang,et al.  National survey of drug-resistant tuberculosis in China. , 2012, The New England journal of medicine.

[245]  Valeria Saraceni,et al.  Heterogeneity in tuberculosis transmission and the role of geographic hotspots in propagating epidemics , 2012, Proceedings of the National Academy of Sciences.

[246]  R. Atun,et al.  Investing in improved performance of national tuberculosis programs reduces the tuberculosis burden: analysis of 22 high-burden countries, 2002-2009. , 2012, The Journal of infectious diseases.

[247]  Xin Wang,et al.  Social Behaviour Risk Factors for Drug Resistant Tuberculosis in Mainland China: A Meta-Analysis , 2012, The Journal of international medical research.

[248]  R. Horton,et al.  A sustainable agenda for tuberculosis control and research , 2012, The Lancet.

[249]  Chaojie Liu,et al.  Factors contributing to the high prevalence of multidrug-resistant tuberculosis: a study from China , 2012, Thorax.

[250]  K. Ukwaja,et al.  The economic burden of tuberculosis care for patients and households in Africa: a systematic review [Review article]. , 2012, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[251]  C. Rodrigues,et al.  Totally drug-resistant tuberculosis in India. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[252]  A. Pawłowski,et al.  Tuberculosis and HIV Co-Infection , 2012, PLoS pathogens.

[253]  J. Pasipanodya,et al.  Multidrug-resistant tuberculosis not due to noncompliance but to between-patient pharmacokinetic variability. , 2011, The Journal of infectious diseases.

[254]  J. Hackman,et al.  Three months of rifapentine and isoniazid for latent tuberculosis infection. , 2011, The New England journal of medicine.

[255]  S. Squire,et al.  A systematic assessment of the concept and practice of public-private mix for tuberculosis care and control , 2011, International journal for equity in health.

[256]  O. Lundberg,et al.  Educational inequalities in tuberculosis mortality in sixteen European populations. , 2011, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[257]  T Cohen,et al.  Modelling the performance of isoniazid preventive therapy for reducing tuberculosis in HIV endemic settings: the effects of network structure , 2011, Journal of The Royal Society Interface.

[258]  S. Keshavjee,et al.  'Sputnik': a programmatic approach to improve tuberculosis treatment adherence and outcome among defaulters. , 2011, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[259]  M. Petticrew,et al.  The social determinants of tuberculosis: from evidence to action. , 2011, American journal of public health.

[260]  Henrik Lindhjem,et al.  Valuing Mortality Risk Reductions from Environmental, Transport, and Health Policies: A Global Meta‐Analysis of Stated Preference Studies , 2011, Risk analysis : an official publication of the Society for Risk Analysis.

[261]  K. Floyd,et al.  Lives saved by tuberculosis control and prospects for achieving the 2015 global target for reducing tuberculosis mortality. , 2011, Bulletin of the World Health Organization.

[262]  M. Raviglione,et al.  Transforming the global tuberculosis response through effective engagement of civil society organizations: the role of the World Health Organization. , 2011, Bulletin of the World Health Organization.

[263]  D. Gwatkin,et al.  Universal health coverage: friend or foe of health equity? , 2011, The Lancet.

[264]  H. Ayles,et al.  The Association between Household Socioeconomic Position and Prevalent Tuberculosis in Zambia: A Case-Control Study , 2011, PloS one.

[265]  P. Ruutu,et al.  MDR‐TB in Finland – still rare despite the situation in our neighbouring countries , 2011, The clinical respiratory journal.

[266]  Gavin Yamey,et al.  Scaling Up Global Health Interventions: A Proposed Framework for Success , 2011, PLoS medicine.

[267]  K. Rasanathan,et al.  The social determinants of health: key to global tuberculosis control. , 2011, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[268]  M. Uplekar,et al.  Global Fund financing of public–private mix approaches for delivery of tuberculosis care , 2011, Tropical medicine & international health : TM & IH.

[269]  K. Castro,et al.  6-month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: a randomised, double-blind, placebo-controlled trial , 2011, The Lancet.

[270]  M. Kimerling,et al.  Size and Usage Patterns of Private TB Drug Markets in the High Burden Countries , 2011, PloS one.

[271]  A. Diacon,et al.  Why Do We Use 600 mg of Rifampicin in Tuberculosis Treatment? , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[272]  M. Perkins,et al.  Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study , 2011 .

[273]  C. Roussos,et al.  MIRU-VNTR typing of drug-resistant tuberculosis isolates in Greece , 2011, Therapeutic advances in respiratory disease.

[274]  Lisa A. Robinson,et al.  The Income Elasticity of the Value per Statistical Life: Transferring Estimates between High and Low Income Populations , 2011, Journal of Benefit-Cost Analysis.

[275]  S. Lawn,et al.  Development of a Standardized Screening Rule for Tuberculosis in People Living with HIV in Resource-Constrained Settings: Individual Participant Data Meta-analysis of Observational Studies , 2011, PLoS medicine.

[276]  Brian G. Williams,et al.  Tuberculosis Incidence in Prisons: A Systematic Review , 2010, PLoS medicine.

[277]  W. Prasitsuebsai,et al.  Pediatric HIVQUAL-T: measuring and improving the quality of pediatric HIV care in Thailand, 2005-2007. , 2010, Joint Commission journal on quality and patient safety.

[278]  K. Mate,et al.  Improving a Mother to Child HIV Transmission Programme through Health System Redesign: Quality Improvement, Protocol Adjustment and Resource Addition , 2010, PloS one.

[279]  R. Hayes,et al.  Comparison of two active case-finding strategies for community-based diagnosis of symptomatic smear-positive tuberculosis and control of infectious tuberculosis in Harare, Zimbabwe (DETECTB): a cluster-randomised trial , 2010, The Lancet.

[280]  H. S. Schaaf,et al.  Childhood tuberculosis: an emerging and previously neglected problem. , 2010, Infectious disease clinics of North America.

[281]  F. Omaswa,et al.  The role of quality improvement in strengthening health systems in developing countries. , 2010, International journal for quality in health care : journal of the International Society for Quality in Health Care.

[282]  R. Atun,et al.  Health-system strengthening and tuberculosis control , 2010, The Lancet.

[283]  Alimuddin Zumla,et al.  Scale-up of services and research priorities for diagnosis, management, and control of tuberculosis: a call to action , 2010, The Lancet.

[284]  Philippe Glaziou,et al.  Tuberculosis control and elimination 2010–50: cure, care, and social development , 2010, The Lancet.

[285]  C. F. von Reyn,et al.  Prevention of tuberculosis in Bacille Calmette–Guérin-primed, HIV-infected adults boosted with an inactivated whole-cell mycobacterial vaccine , 2010, AIDS.

[286]  R. O'brien,et al.  Rapid screening of MDR-TB using molecular Line Probe Assay is feasible in Uganda , 2010, BMC infectious diseases.

[287]  R. Chaisson,et al.  Community-randomized trial of enhanced DOTS for tuberculosis control in Rio de Janeiro, Brazil. , 2010, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[288]  S. Lawn,et al.  Yield of HIV-associated tuberculosis during intensified case finding in resource-limited settings: a systematic review and meta-analysis , 2010, The Lancet. Infectious diseases.

[289]  T. Shimao.  [Tuberculosis prevalence survey in Japan]. , 2009, Kekkaku : [Tuberculosis].

[290]  C. Dye,et al.  Trends in tuberculosis incidence and their determinants in 134 countries. , 2009, Bulletin of the World Health Organization.

[291]  C. Sreeramareddy,et al.  Time delays in diagnosis of pulmonary tuberculosis: a systematic review of literature , 2009, BMC infectious diseases.

[292]  C. Dye,et al.  Drivers of tuberculosis epidemics: the role of risk factors and social determinants. , 2009, Social science & medicine.

[293]  H. McShane,et al.  Viral Booster Vaccines Improve Mycobacterium bovis BCG-Induced Protection against Bovine Tuberculosis , 2009, Infection and Immunity.

[294]  C. Hamilton,et al.  Costs and cost-effectiveness of four treatment regimens for latent tuberculosis infection. , 2009, American journal of respiratory and critical care medicine.

[295]  C. Sismanidis,et al.  Prevalence of Tuberculosis, HIV and Respiratory Symptoms in Two Zambian Communities: Implications for Tuberculosis Control in the Era of HIV , 2009, PloS one.

[296]  B. Lindtjørn,et al.  Health Extension Workers Improve Tuberculosis Case Detection and Treatment Success in Southern Ethiopia: A Community Randomized Trial , 2009, PloS one.

[297]  N. Chang,et al.  Assessment of changes in knowledge and stigmatization following tuberculosis training workshops in taiwan. , 2009, Journal of the Formosan Medical Association = Taiwan yi zhi.

[298]  A. Thomas,et al.  MVA.85A Boosting of BCG and an Attenuated, phoP Deficient M. tuberculosis Vaccine Both Show Protective Efficacy Against Tuberculosis in Rhesus Macaques , 2009, PloS one.

[299]  Michael JA Reid,et al.  Approaches to tuberculosis screening and diagnosis in people with HIV in resource-limited settings. , 2009, The Lancet. Infectious diseases.

[300]  Robert Beaglehole,et al.  Global public health: a scorecard , 2008, The Lancet.

[301]  S. Maloney,et al.  Multidrug-Resistant Tuberculosis 
Outbreak among US-bound Hmong 
Refugees, Thailand, 2005 , 2008, Emerging infectious diseases.

[302]  Peter G. Smith,et al.  Rate and amplification of drug resistance among previously-treated patients with tuberculosis in Kampala, Uganda. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[303]  Ubiratan de Paula Santos,et al.  Tuberculose e silicose: epidemiologia, diagnóstico e quimioprofilaxia , 2008 .

[304]  M. Raviglione,et al.  Global epidemiology of tuberculosis: prospects for control. , 2008, Seminars in respiratory and critical care medicine.

[305]  H. Ayles,et al.  Cost of tuberculosis diagnosis and treatment from the patient perspective in Lusaka, Zambia. , 2008, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[306]  F. Cobelens,et al.  Scaling Up Programmatic Management of Drug-Resistant Tuberculosis: A Prioritized Research Agenda , 2008, PLoS medicine.

[307]  P. Hopewell,et al.  Tuberculosis and latent tuberculosis infection in close contacts of people with pulmonary tuberculosis in low-income and middle-income countries: a systematic review and meta-analysis. , 2008, The Lancet. Infectious diseases.

[308]  K. Hofman,et al.  Implementation Science , 2007, Science.

[309]  E. Nardell,et al.  Tuberculosis infection control in resource-limited settings in the era of expanding HIV care and treatment. , 2007, The Journal of infectious diseases.

[310]  B. Simwaka,et al.  Can Malawi's poor afford free tuberculosis services? Patient and household costs associated with a tuberculosis diagnosis in Lilongwe. , 2007, Bulletin of the World Health Organization.

[311]  J. Macq,et al.  Patient empowerment in tuberculosis control: reflecting on past documented experiences , 2007, Tropical medicine & international health : TM & IH.

[312]  D. Evans,et al.  Protecting households from catastrophic health spending. , 2007, Health affairs.

[313]  M. Bates,et al.  Risk of tuberculosis from exposure to tobacco smoke: a systematic review and meta-analysis. , 2007, Archives of internal medicine.

[314]  M. Ezzati,et al.  Tobacco Smoke, Indoor Air Pollution and Tuberculosis: A Systematic Review and Meta-Analysis , 2007, PLoS medicine.

[315]  M. Uplekar,et al.  Hard gains through soft contracts: productive engagement of private providers in tuberculosis control. , 2006, Bulletin of the World Health Organization.

[316]  K. Floyd,et al.  Cost and cost-effectiveness of PPM-DOTS for tuberculosis control: evidence from India. , 2006, Bulletin of the World Health Organization.

[317]  A. Grant,et al.  Isoniazid Preventive Therapy and Risk for Resistant Tuberculosis , 2006, Emerging infectious diseases.

[318]  William Rodriguez,et al.  Priorities in tuberculosis research , 2006, The Lancet.

[319]  M. Uplekar,et al.  WHO's new Stop TB Strategy , 2006, The Lancet.

[320]  C. Chee,et al.  Contact screening and latent TB infection treatment in Singapore correctional facilities. , 2005, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[321]  V. Chadha.  Tuberculosis epidemiology in India: a review. , 2005, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[322]  L. Jacobsson,et al.  Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. , 2005, Arthritis and rheumatism.

[323]  S. Niemann,et al.  The Beijing genotype is emerging among multidrug-resistant Mycobacterium tuberculosis strains from Germany. , 2004, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[324]  C. Murray,et al.  Household catastrophic health expenditure: a multicountry analysis , 2003, The Lancet.

[325]  C. Dye,et al.  The dynamics of tuberculosis in response to 10 years of intensive control effort in Peru. , 2001, The Journal of infectious diseases.

[326]  John Chan,et al.  Tuberculosis: Latency and Reactivation , 2001, Infection and Immunity.

[327]  P. Farmer,et al.  Effect of Administering Short-Course, Standardized Regimens in Individuals Infected with Drug-Resistant Mycobacterium tuberculosis Strains , 2000, European Journal of Clinical Microbiology and Infectious Diseases.

[328]  R. Croft,et al.  Knowledge, attitude and practice regarding leprosy and tuberculosis in Bangladesh. , 1999, Leprosy review.

[329]  F. March,et al.  Acquired drug resistance in Mycobacterium tuberculosis isolates recovered from compliant patients with human immunodeficiency virus-associated tuberculosis. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[330]  C. Macintyre,et al.  Impact of tuberculosis control measures and crowding on the incidence of tuberculous infection in Maryland prisons. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[331]  T. Frieden,et al.  Tuberculosis in New York City--turning the tide. , 1995, The New England journal of medicine.

[332]  M. Uplekar,et al.  Treatment of tuberculosis by private general practitioners in India. , 1991, Tubercle.

[333]  T. Beard,et al.  DECLARATION OF ALMA-ATA , 1979, The Lancet.

[334]  N. Fendall.  DECLARATION OF ALMA-ATA , 1978, The Lancet.

[335]  E. Lincoln.  The effect of antimicrobial therapy on the prognosis of primary tuberculosis in children. , 1954, American review of tuberculosis.

[336]  P. Escalante.  Tuberculosis , 1904, Annals of Internal Medicine.

[337]  W. Wells,et al.  How tuberculosis programs can navigate the world of social health insurance. , 2019, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[338]  T. Burki.  The global cost of tuberculosis. , 2018, The Lancet. Respiratory medicine.

[339]  M. Uplekar,et al.  Tuberculosis makes it onto the international political agenda for health…finally. , 2018, The Lancet. Global health.

[340]  Stephanie Law,et al.  Emergence of drug resistance in patients with tuberculosis cared for by the Indian health-care system: a dynamic modelling study. , 2017, The Lancet. Public health.

[341]  K. Chalkidou,et al.  Implementing pro-poor universal health coverage. , 2016, The Lancet. Global health.

[342]  B. D. de Jong,et al.  A four-month gatifloxacin-containing regimen for treating tuberculosis. , 2015, The New England journal of medicine.

[343]  Ted Cohen,et al.  Spontaneous Emergence of Multiple Drug Resistance in Tuberculosis before and during Therapy , 2011, PloS one.

[344]  R. Zaha,et al.  Effects of Ecuador's national monetary incentive program on adherence to treatment for drug-resistant tuberculosis. , 2014, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[345]  G. Bartlett,et al.  Evaluating the role of primary care physicians in the treatment of latent tuberculosis: a population study. , 2014, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[346]  H. McIlleron,et al.  Principles for designing future regimens for multidrug-resistant tuberculosis. , 2014, Bulletin of the World Health Organization.

[347]  M. Uplekar,et al.  Systematic screening for active tuberculosis: rationale, definitions and key considerations [State of the art series. Active case finding/screening. Number 1 in the series]. , 2013, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[348]  R. F. Viergever.  The mismatch between the health research and development (R&D) that is needed and the R&D that is undertaken: an overview of the problem, the causes, and solutions. , 2013, Global health action.

[349]  M. Pai,et al.  New tuberculosis technologies: challenges for retooling and scale-up [State of the art series. New tools. Number 4 in the series]. , 2012, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[350]  J. Creswell,et al.  Tuberculosis and poverty: what is being done. , 2011, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[351]  R. Atun,et al.  A systematic review of the evidence on integration of targeted health interventions into health systems. , 2010, Health policy and planning.

[352]  A. Grant,et al.  Prevalence of latent tuberculosis infection among gold miners in South Africa. , 2009, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[353]  Finn E. Kydland,et al.  Expert Panel Ranking , 2009 .

[354]  I. Smith,et al.  The Global TB Drug Facility: innovative global procurement. , 2004, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[355]  M. Uplekar,et al.  Involving private practitioners in tuberculosis control: issues, interventions, and emerging policy framework , 2001 .

[356]  D. Mitchison.  How drug resistance emerges as a result of poor compliance during short course chemotherapy for tuberculosis. , 1998, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[357]  D. Rock.  Tuberculosis: a global emergency. , 1997, Work.

[358]  S. Ferebee.  Controlled chemoprophylaxis trials in tuberculosis. A general review. , 1970, Bibliotheca tuberculosea.

[359]  Ferebee Sh.  Controlled chemoprophylaxis trials in tuberculosis. A general review. , 1970 .

[360]  G. Comstock,et al.  Decline of the tuberculosis epidemic in Alaska. , 1961, Public health reports.

[361]  BMC Infectious Diseases BioMed Central Research article The Recent-Transmission of Mycobacterium tuberculosis Strains among Iranian and Afghan Relapse Cases: a DNA-fingerprinting using RFLP and spoligotyping , 2022 .